Rapport Therapeutics, Inc. RAPP Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Rapport Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: Rapport Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rapport Therapeutics, Inc.'s accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rapport Therapeutics, Inc.'s accrued expenses?
- Rapport Therapeutics, Inc. (RAPP) reported accrued expenses of $8.72M in Q1 2026.
- How has Rapport Therapeutics, Inc.'s accrued expenses changed year-over-year?
- Rapport Therapeutics, Inc.'s accrued expenses increased by 39.8% year-over-year, from $6.24M to $8.72M.
- What is the long-term trend for Rapport Therapeutics, Inc.'s accrued expenses?
- Over 2 years (2023 to 2025), Rapport Therapeutics, Inc.'s accrued expenses has grown at a 46.6% compound annual growth rate (CAGR), from $5.63M to $12.1M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.